Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FNTA | P49354 | 7/20 | 0.48 |
| ▸ | FNTB | P49356 | 7/20 | 0.48 |
| ▸ | PGGT1B | P53609 | 4/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.47 |
| ▸ | CA2 | P00918 | 2/20 | 0.46 |
| ▸ | CA1 | P00915 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9828832 | 1.00 | FNTA (0.48) | FNTAFNTBPGGT1BLMNAFOLH1 | |
| SCHEMBL2547678 | 1.00 | FNTA (0.48) | FNTAFNTBPGGT1BLMNAFOLH1 | |
| SCHEMBL30051639 | 0.97 | FNTA (0.47) | FNTAFNTBPGGT1BLMNA | |
| SCHEMBL30051411 | 0.94 | FNTA (0.44) | FNTAFNTBPGGT1BLMNAFOLH1 | |
| SCHEMBL30051956 | 0.93 | FNTA (0.53) | FNTAFNTBPGGT1B | |
| SCHEMBL9831127 | 0.92 | FNTA (0.48) | FNTAFNTBPGGT1BLMNA | |
| SCHEMBL30051807 | 0.92 | FOLH1 (0.53) | FNTAFNTBPGGT1BFOLH1 | |
| SCHEMBL9831123 | 0.92 | FNTA (0.48) | FNTAFNTBPGGT1BLMNA | |
| SCHEMBL6067630 | 0.92 | FNTA (0.51) | FNTAFNTBPGGT1B | |
| SCHEMBL6067624 | 0.92 | FNTA (0.51) | FNTAFNTBPGGT1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250032573-A1 | IMMUNITY-ENHANCING PEPTIDE ANALOGS AND USES THEREOF | Research & Business Foundation Sungkyunkwan University (KR) | 2025-01-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250032573-A1 | IMMUNITY-ENHANCING PEPTIDE ANALOGS AND USES THEREOF | FPR3, FPR1, FPR2 | FNTA 1173/4885FNTB 949/4885PGGT1B 3240/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.